# Full Product Catalog

Complete reference guide for all compounds in the CULTR library, organized by therapeutic category with mechanism of action and signaling pathway detail.

---

## Metabolic / Body Composition

### 5-Amino-1MQ
- **Primary Target**: NNMT (Nicotinamide N-methyltransferase) inhibition
- **Downstream Effects**:
  - ↑ NAD+ salvage pathway flux
  - ↑ SIRT1 activity (indirect)
  - ↑ Mitochondrial biogenesis signaling
  - ↑ AMPK activation
  - Improved adipocyte metabolic signaling
- **Common Uses**: Fat loss, metabolic optimization, cellular energy
- **Best For**: Body recomposition via metabolic pathway enhancement

### AOD-9604
- **Primary Target**: Fragment of GH (176–191 region)
- **Receptor Interaction**: Weak GH receptor activity (non-growth signaling)
- **Downstream Effects**:
  - ↑ Lipolysis (HSL activation)
  - ↓ Lipogenesis
  - Limited IGF-1 stimulation
- **Standard Dose**: 250–500mcg daily
- **Half-life**: 1–2 hours
- **Routes**: Subcutaneous
- **Common Uses**: Fat loss without muscle loss
- **Best For**: Body recomposition, targeted fat reduction
- **Cycle**: 8–12 weeks

---

## GLP-1 / Incretin Family

### Semaglutide
- **Primary Target**: GLP-1 receptor (GLP1R; Gs-coupled GPCR)
- **Pathways**:
  - ↑ cAMP → PKA activation
  - ↑ Insulin secretion (glucose-dependent)
  - ↓ Glucagon
  - Delayed gastric emptying
  - CNS satiety signaling (hypothalamus)
- **Standard Dose**: 0.25–2.4mg weekly (slow titration)
- **Half-life**: 7 days
- **Routes**: Subcutaneous
- **Common Uses**: Weight loss, glucose control
- **Best For**: Metabolic optimization, fat loss
- **Cycle**: Ongoing

### Tirzepatide
- **Primary Targets**: GLP1R + GIP receptor (GIPR)
- **Pathways**:
  - Dual incretin signaling
  - ↑ β-cell insulinotropic response
  - ↑ Adipocyte insulin sensitivity
  - Enhanced metabolic flexibility
- **Standard Dose**: 2.5–15mg weekly (slow titration)
- **Half-life**: 5 days
- **Routes**: Subcutaneous
- **Common Uses**: Weight loss, glycemic control, metabolic enhancement
- **Best For**: Dual-pathway metabolic optimization
- **Cycle**: Ongoing

### Retatrutide (RTA)
- **Primary Targets**: GLP1R + GIPR + Glucagon receptor (GCGR)
- **Pathways**:
  - ↑ Energy expenditure (via GCGR)
  - ↑ Lipolysis
  - ↑ Insulinotropic signaling
  - ↑ Hepatic fat oxidation
- **Standard Dose**: 1–12mg weekly (slow titration)
- **Half-life**: Days
- **Routes**: Subcutaneous
- **Common Uses**: Weight loss, metabolic optimization, appetite control
- **Best For**: Maximum metabolic enhancement; CULTR's primary GLP recommendation
- **Cycle**: Ongoing

### Mazdutide
- **Primary Targets**: GLP1R + Glucagon receptor
- **Pathways**:
  - ↑ Energy expenditure
  - ↑ Weight reduction via dual mechanism
  - Hepatic metabolic modulation
- **Routes**: Subcutaneous
- **Common Uses**: Weight loss, metabolic optimization
- **Best For**: Dual-agonist metabolic support
- **Cycle**: Ongoing

### Cagrilintide
- **Mechanism**: Amylin receptor agonist; dual GI/CNS effects
- **Standard Dose**: 0.25–2.4mg weekly (slow titration)
- **Half-life**: Days
- **Routes**: Subcutaneous
- **Common Uses**: Weight loss, appetite suppression
- **Best For**: Significant fat loss goals
- **Cycle**: Ongoing

---

## GH Axis

### CJC-1295 (No DAC)
- **Primary Target**: GHRH receptor (GHRHR; Gs GPCR)
- **Pathways**:
  - ↑ cAMP → PKA
  - ↑ Pituitary GH release
  - ↑ Hepatic IGF-1 production
- **Standard Dose**: 100mcg nightly
- **Half-life**: Short (No DAC)
- **Common Uses**: GH pulse optimization
- **Best Stacked With**: Ipamorelin (synergistic effect)
- **Cycle**: 8–12 weeks

### CJC-1295 (With DAC)
- **Primary Target**: GHRH receptor (GHRHR; Gs GPCR)
- **Pathways**:
  - Same receptor as No DAC variant, extended half-life
  - Prolonged GH pulsatility enhancement
  - ↑ cAMP → PKA
  - ↑ Pituitary GH release
  - ↑ Hepatic IGF-1 production
- **Common Uses**: Sustained GH elevation, recovery, body composition
- **Best For**: Extended GH support without daily dosing

### Sermorelin (GRF 1-29)
- **Primary Target**: GHRHR
- **Pathways**:
  - ↑ cAMP → PKA
  - ↑ Pituitary GH release
  - ↑ Hepatic IGF-1 production
- **Standard Dose**: 200–300mcg daily or before bed
- **Half-life**: 7 minutes
- **Common Uses**: Natural GH elevation, sleep
- **Side Effects**: Minimal; generally well-tolerated
- **Cycle**: 3–6 months

### Ipamorelin
- **Primary Target**: GHSR-1a (Ghrelin receptor; Gq-coupled)
- **Pathways**:
  - ↑ Intracellular Ca²⁺
  - ↑ GH pulsatile release
  - Minimal cortisol/prolactin stimulation
- **Standard Dose**: 200–300mcg 1–3x daily
- **Half-life**: 2 hours
- **Common Uses**: GH secretion without metabolic stress
- **Best For**: Athletes, endurance, natural GH enhancement
- **Cycle**: 8–12 weeks

### GHRP-2 / GHRP-6
- **Primary Target**: GHSR-1a
- **Pathways**:
  - ↑ GH secretion
  - ↑ ACTH / cortisol (stronger than Ipamorelin)
  - ↑ Prolactin
- **Common Uses**: GH release, appetite stimulation (GHRP-6)
- **Best For**: Potent GH secretion when stronger stimulus needed

### Hexarelin
- **Primary Target**: GHSR-1a
- **Pathways**:
  - Potent GH release
  - Cardiac GH receptor stimulation
  - Possible desensitization risk
- **Common Uses**: GH elevation, cardiac tissue support
- **Note**: May require cycling due to desensitization

### Tesamorelin
- **Primary Target**: GHRHR
- **Pathways**:
  - ↑ GH → ↑ IGF-1
  - ↓ Visceral adipose tissue
- **Common Uses**: Visceral fat reduction, GH optimization
- **Best For**: Targeted visceral fat loss

### IGF-1 LR3 (Insulin-Like Growth Factor-1 Long R3)
- **Primary Target**: IGF-1 receptor (IGF1R; RTK)
- **Pathways**:
  - PI3K → AKT → mTOR
  - MAPK/ERK
  - ↑ Protein synthesis
  - ↑ Cellular proliferation
- **Standard Dose**: 20–50mcg daily
- **Half-life**: 20–30 hours
- **Common Uses**: Lean muscle gain, strength, recovery
- **Stacks Well With**: CJC-1295, Ipamorelin, BPC-157
- **Cycle**: 4–6 weeks on, 4 weeks off

---

## Repair / Regeneration

### BPC-157 (Body Protection Compound-157)
- **Targets (proposed)**:
  - VEGFR2
  - Nitric oxide pathway modulation
  - FAK signaling
- **Pathways**:
  - ↑ Angiogenesis
  - ↑ Fibroblast migration
  - ↑ Collagen deposition
  - Cytoprotective signaling
- **Standard Dose**: 250–500mcg 1–2x daily
- **Half-life**: Hours
- **Routes**: IM, SQ, Intranasal, Oral
- **Common Uses**: Tendon healing, joint recovery, GI health
- **Cycle**: 4–12 weeks

### TB-500 (Thymosin Beta-4 Fragment)
- **Target**: Actin-binding protein modulation
- **Pathways**:
  - ↑ Cell migration
  - ↑ Angiogenesis
  - ↑ Tissue remodeling
- **Standard Dose**: 2.5–5mg 2x weekly
- **Half-life**: Hours
- **Routes**: Subcutaneous, Intramuscular
- **Common Uses**: Athletic recovery, tissue repair
- **Best For**: General health maintenance post-injury
- **Cycle**: 4–12 weeks

### GHK-Cu (Copper Peptide Complex)
- **Primary Target**: Copper-binding peptide; gene expression modulation
- **Pathways**:
  - ↑ Collagen I & III
  - ↑ MMP modulation
  - ↑ Tissue remodeling genes
  - Anti-inflammatory gene regulation
- **Standard Dose**: 1–2mg daily
- **Half-life**: Hours
- **Routes**: Topical, Subcutaneous, Intranasal
- **Common Uses**: Skin health, collagen, joint support
- **Best For**: Long-term collagen enhancement
- **Cycle**: 8–16 weeks

### KPV
- **Target**: Melanocortin-1 receptor (MC1R)
- **Pathways**:
  - ↓ NF-κB
  - ↓ TNF-α
  - Anti-inflammatory signaling
- **Common Uses**: Gut health, inflammatory conditions, tissue repair
- **Best For**: Targeted anti-inflammatory support

### LL-37
- **Target**: FPR2 receptor
- **Pathways**:
  - Antimicrobial membrane disruption
  - Immunomodulation
  - Chemotaxis signaling
- **Common Uses**: Immune defense, antimicrobial support, wound healing
- **Best For**: Infection resistance and immune enhancement

### GLOW Blend
- **Mechanism**: Multiple peptides; comprehensive recovery
- **Standard Dose**: Per component guidelines
- **Common Uses**: Athletic recovery, general wellness
- **Composition**: BPC-157 + TB-500 + GHK-Cu
- **Cycle**: 8–12 weeks

---

## Mitochondrial

### SS-31 / Elamipretide
- **Target**: Inner mitochondrial membrane (cardiolipin binding)
- **Pathways**:
  - Stabilizes electron transport chain
  - ↓ ROS
  - ↑ ATP production efficiency
- **Standard Dose**: 10–40mg daily
- **Half-life**: Hours
- **Routes**: Intravenous, Subcutaneous
- **Common Uses**: Cellular energy, fatigue reduction
- **Best For**: Mitochondrial dysfunction, aging
- **Cycle**: 4–12 weeks

### MOTS-c
- **Target**: AMPK activation
- **Pathways**:
  - ↑ Glucose uptake
  - ↑ Fat oxidation
  - ↑ Insulin sensitivity
- **Common Uses**: Metabolic regulation, exercise mimetic effects
- **Best For**: Metabolic resilience and mitochondrial health

### NAD+
- **Target**: Sirtuins (SIRT1–7), PARPs
- **Pathways**:
  - ↑ DNA repair
  - ↑ Mitochondrial biogenesis
  - ↑ Cellular stress resistance
- **Common Uses**: Anti-aging, energy production, cellular repair
- **Best For**: Longevity optimization, neuroprotection

---

## Neurocognitive

### Selank
- **Target**: GABAergic modulation
- **Pathways**:
  - ↑ BDNF
  - Anxiolytic signaling
  - Modulation of monoamine turnover
- **Standard Dose**: 250–500mcg daily (intranasal)
- **Half-life**: Hours
- **Routes**: Intranasal (primarily)
- **Common Uses**: Anxiety reduction, mood balance
- **Best For**: Mental health support
- **Cycle**: 4–8 weeks

### Semax
- **Target**: Melanocortin receptors (MC4R partial activity)
- **Pathways**:
  - ↑ BDNF
  - ↑ Dopaminergic signaling
  - Neuroprotection
- **Standard Dose**: 200–600mcg daily (intranasal)
- **Half-life**: Hours
- **Routes**: Intranasal (primarily)
- **Common Uses**: Cognitive enhancement, memory
- **Best For**: Mental clarity, learning
- **Cycle**: 4–8 weeks

### DSIP (Delta Sleep-Inducing Peptide)
- **Proposed Target**: Unknown; delta sleep modulation
- **Pathways**:
  - Sleep architecture regulation
  - HPA modulation
- **Standard Dose**: 100–500mcg at bedtime
- **Half-life**: Hours
- **Routes**: Intranasal, Subcutaneous, Intravenous
- **Common Uses**: Sleep quality, recovery enhancement
- **Best For**: Sleep optimization
- **Cycle**: 4–12 weeks

### Pinealon
- **Target**: Gene expression modulation in pineal tissue
- **Pathways**:
  - Circadian rhythm regulation
  - Neuroprotective signaling
- **Common Uses**: Sleep regulation, circadian support, neuroprotection
- **Best For**: Circadian rhythm optimization

---

## Reproductive / Libido

### PT-141 (Bremelanotide)
- **Target**: MC4R
- **Pathways**:
  - ↑ Sexual arousal signaling (CNS)
  - ↑ Dopaminergic tone
- **Common Uses**: Sexual dysfunction, libido enhancement
- **Best For**: CNS-mediated sexual function support

### Kisspeptin
- **Target**: KISS1R (GPR54)
- **Pathways**:
  - ↑ GnRH release
  - ↑ LH / FSH → ↑ Testosterone / Estrogen
- **Common Uses**: Hormonal optimization, fertility support
- **Best For**: Reproductive hormone signaling

### Gonadorelin
- **Target**: GnRH receptor
- **Pathways**:
  - Direct stimulation of LH/FSH release
- **Common Uses**: Hormonal support, fertility
- **Best For**: Pituitary gonadotropin stimulation

---

## Immune

### Thymosin Alpha-1
- **Target**: TLR modulation
- **Pathways**:
  - ↑ T-cell differentiation
  - ↑ NK cell activity
  - ↑ Immune surveillance
- **Standard Dose**: 1.6–4.5mg 2–3x weekly
- **Half-life**: Hours
- **Routes**: Subcutaneous, Intramuscular
- **Common Uses**: Immune support, general health
- **Best For**: Immune system optimization
- **Cycle**: 4–16 weeks, can be ongoing

### Thymulin
- **Target**: T-cell maturation pathways
- **Pathways**:
  - Immune regulation
  - Anti-inflammatory cytokine balance
- **Common Uses**: Immune modulation, inflammation management
- **Best For**: Adaptive immune support

### Thymalin
- **Target**: Thymic peptide fraction
- **Pathways**:
  - Immune modulation
  - Hematopoietic support
- **Common Uses**: Immune restoration, aging-related immune decline
- **Best For**: Thymic function restoration

### VIP (Vasoactive Intestinal Peptide)
- **Target**: VPAC1 / VPAC2 (Gs GPCR)
- **Pathways**:
  - ↑ cAMP
  - Vasodilation
  - Anti-inflammatory cytokine signaling
- **Common Uses**: Inflammatory conditions, GI health, respiratory support
- **Best For**: Broad anti-inflammatory and vasodilatory effects

---

## Aesthetic / Pigment

### Melanotan I
- **Target**: MC1R
- **Pathways**:
  - ↑ Melanin synthesis
- **Common Uses**: Skin pigmentation, UV protection
- **Best For**: Even, natural-looking tan enhancement

### Melanotan II
- **Target**: MC1R / MC4R
- **Pathways**:
  - ↑ Pigmentation
  - ↑ Libido signaling
- **Common Uses**: Tanning, libido enhancement
- **Best For**: Dual pigmentation and sexual function support

---

## Muscle Growth

### MGF / PEG-MGF (Mechano Growth Factor)
- **Target**: IGF-1 receptor (local autocrine)
- **Pathways**:
  - Satellite cell activation
  - PI3K/AKT/mTOR
  - Muscle repair signaling
- **Common Uses**: Muscle hypertrophy, post-exercise recovery
- **Best For**: Localized muscle growth and repair

### Follistatin 344
- **Mechanism**: Myostatin antagonist; muscle deregulation
- **Standard Dose**: 100–300mcg daily for 10–30 days
- **Half-life**: Hours
- **Common Uses**: Significant muscle growth
- **Administration**: Typically pulsed (on/off cycles)
- **Cycle**: Monthly pulses; ongoing protocol

---

## Other

### SNAP-8
- **Target**: SNARE complex inhibition
- **Pathways**:
  - ↓ Neurotransmitter release
  - Cosmetic wrinkle modulation
- **Common Uses**: Anti-wrinkle, cosmetic peptide
- **Best For**: Topical expression line reduction

### SLU-PP-332
- **Target**: ERR (Estrogen-related receptors)
- **Pathways**:
  - ↑ Oxidative metabolism
  - ↑ Fat oxidation
  - Mitochondrial gene expression
- **Common Uses**: Exercise mimetic, metabolic enhancement
- **Best For**: Endurance and metabolic optimization

### Epitalon
- **Mechanism**: Telomerase activation; pineal function
- **Standard Dose**: 5–10mg before bed (10-day cycles)
- **Half-life**: Hours
- **Routes**: Subcutaneous, Intranasal
- **Common Uses**: Anti-aging, longevity, sleep
- **Best For**: Long-term health optimization
- **Cycle**: 10–20 days on, 20 days off

---

## Optimal Timing Guide — All Products

### MORNING (FASTED OR EARLY DAY)

| Peptide | Timing | Notes |
|---------|--------|-------|
| AOD-9604 | Morning or pre-cardio | Fat loss; empty stomach |
| 5-Amino-1MQ | Morning | Metabolic activation |
| Semax | Morning/early afternoon | Cognitive; avoid late PM |
| Selank | Morning or as needed | Anxiolytic; avoid evening |
| Thymosin Alpha-1 | Morning | Immune rhythm support |
| Elamipretide (SS-31) | Morning (fasted) | Mitochondrial energy |
| MOTS-c | Morning | Metabolic regulation |
| NAD+ | Morning | Cellular energy support |
| RTA / Semaglutide / Tirzepatide / Mazdutide / Cagrilintide | Same day weekly | Consistent timing |

### EVENING / PRE-SLEEP

| Peptide | Timing | Notes |
|---------|--------|-------|
| Sermorelin | Pre-sleep | GH pulse; empty stomach 2–3h |
| Epitalon | Before bed | Pineal/circadian support |
| Pinealon | Before bed | Circadian rhythm regulation |
| CJC-1295 (No DAC) + Ipamorelin | Pre-sleep | Synergistic GH pulse; fasted |
| DSIP | 30–60 min before bed | Delta sleep induction |
| GHK-Cu | Evening | Repair, skin regeneration |
| Tesamorelin | Evening | GH optimization |

### PRE-WORKOUT / DAYTIME

| Peptide | Timing | Notes |
|---------|--------|-------|
| IGF-1 LR3 | Pre-workout | Muscle signaling; avoid food 2–3h |
| MGF / PEG-MGF | Post-workout | Satellite cell activation |
| Follistatin | Pre-workout or AM | Myostatin inhibition |
| BPC-157 | Near training (optional) | Can dose near injury site |
| TB-500 | Flexible | Recovery support |

### FLEXIBLE / SITUATIONAL

| Peptide | Timing | Notes |
|---------|--------|-------|
| PT-141 | 30–60 min before desired effect | Sexual function |
| Kisspeptin | 30–60 min before desired effect | GnRH trigger |
| Gonadorelin | As directed | Hormonal support |
| Melanotan I/II | Pre-sun exposure | 30–60 min before UV |
| KPV | As directed | Anti-inflammatory support |
| LL-37 | As directed | Antimicrobial support |
| VIP | As directed | Anti-inflammatory / vasodilation |
| BPC-157 / TB-500 | Flexible | Consistency > exact timing |
| SLU-PP-332 | Morning or pre-exercise | Exercise mimetic |

### CRITICAL TIMING RULES

| Rule | Guideline |
|------|-----------|
| **GH-related peptides** | Avoid food 2–3 hours before; insulin blunts GH release |
| **Metabolic/fat loss** | Fasted morning or pre-cardio; consistency > exact hour |
| **CNS peptides (Semax, Selank)** | Avoid late night to prevent sleep disruption |
| **Sleep peptides (DSIP, Pinealon)** | 30–60 min before bed; do not combine with sedatives |
| **GLP-1 weekly injections** | Same day and time every week |
| **Repair peptides (BPC, TB-500)** | Timing flexible; some prefer near injury site |
| **Immune peptides** | Morning dosing aligns with circadian immune rhythm |

---

## General Administration Guidelines

### Reconstitution
- Use bacteriostatic water (0.9% benzyl alcohol)
- Mix gently; avoid vigorous shaking
- Solution typically stable 30 days refrigerated
- Label with reconstitution date

### Injection Technique
- **SQ**: Subcutaneous layer (belly, thigh, arm)
- **IM**: Intramuscular (glute, quad, deltoid)
- Rotate injection sites to avoid lipohypertrophy
- Maintain sterile technique always

### Storage
- **Powder**: Refrigerated (2–8°C) or room temp (varies)
- **Reconstituted**: Always refrigerated (2–8°C)
- Away from light exposure
- Check for clarity/discoloration before use

## Important Medical Disclaimer

All information provided is for educational and research purposes only. These compounds are not approved for human consumption in most jurisdictions. This information should not be construed as medical advice. Always consult with qualified healthcare providers before considering any compound. CULTR Health does not recommend, endorse, or provide medical guidance for human use of these substances.
